InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.041 0.003 (7.89%)+
Announcement
Release
24 Mar 2026 9:43AM
Price at Release
$0.038
Full Release
download
Summary
Emyria Limited, a leader in developing innovative mental health treatments, announced the progress of its first Victorian Empax clinic, set to commence treatments in Q2 CY2026. The clinic is a key part of Emyria’s national rollout strategy, expected to enhance the company's capacity to deliver reimbursable, evidence-based mental health treatments. The company has successfully contracted and trained 31 Victorian therapists and four psychiatrists to support the clinic's operations. Additionally, operational readiness is advancing with secure medication supply and a finalized agreement with Avive Health. Dual reimbursement pathways through Medibank Private and the Department of Veterans’ Affairs are in place, supporting revenue generation and reducing patient self-funding reliance. All regulatory and operational workstreams remain on schedule for the Q2 2026 launch, aiming to expand Emyria’s treatment footprint and scale the Empax model nationwide.
Key Points
  • Emyria's first Victorian Empax clinic scheduled for Q2 CY2026.
  • 31 Victorian therapists and 4 psychiatrists contracted and trained.
  • Finalized agreement with Avive Health and medication supply secured.
  • Dual reimbursement pathways through Medibank Private and Department of Veterans’ Affairs.
  • Clinic aims to expand Emyria’s treatment footprint and scale nationally.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.